Singh Jugraj, Gupta Palak, Vargas Juan, Kudelka Andrzej, Kobe Margaret, Rocca Neychelle
Internal Medicine, Northern Arizona Healthcare, Cottonwood, USA.
Internal Medicine, Maharishi Markandeshwar Institute of Medical Sciences and Research, Ambala, IND.
Cureus. 2025 Apr 24;17(4):e82952. doi: 10.7759/cureus.82952. eCollection 2025 Apr.
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is widely used in the treatment of chronic lymphocytic leukemia (CLL). However, its use is associated with a range of adverse effects, including cutaneous manifestations. We present a case of a 74-year-old male with CLL who developed a perianal rash following four years of ibrutinib therapy. The rash progressively worsened due to a superimposed bacterial infection, resulting in perianal cellulitis with bleeding, severe pain, and difficulty passing stools. The patient was started on antibiotics, and ibrutinib was discontinued. This case highlights an unusual presentation of ibrutinib-induced skin toxicity in the perianal region, complicated by bacterial infection, and underscores the importance of early recognition and management. To the best of our knowledge, this is the first report of such a manifestation, contributing new insights into the spectrum of ibrutinib-associated cutaneous adverse effects.
伊布替尼是一种布鲁顿酪氨酸激酶（BTK）抑制剂，广泛用于治疗慢性淋巴细胞白血病（CLL）。然而，其使用与一系列不良反应相关，包括皮肤表现。我们报告一例74岁男性CLL患者，在接受伊布替尼治疗四年后出现肛周皮疹。由于叠加细菌感染，皮疹逐渐加重，导致肛周蜂窝织炎伴出血、剧痛及排便困难。患者开始使用抗生素治疗，并停用伊布替尼。该病例突出了伊布替尼诱导的肛周皮肤毒性的不寻常表现，并伴有细菌感染，强调了早期识别和处理的重要性。据我们所知，这是此类表现的首例报告，为伊布替尼相关皮肤不良反应的范围提供了新的见解。
